Strategic Divestiture and Financial Flexibility: HLS Therapeutics Inc's Optimistic Buy Rating
Stifel Nicolaus Keeps Their Hold Rating on HLS Therapeutics Inc (HLS)
Stocks in Play: HLS Therapeutics Inc.
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence With Clozapine Treatment
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
HLS Therapeutics (HLS.TO) reported a wider first quarter net loss than in the year earlier period as revenue fell. The company has also terminated its agreement with Pfizer. The pharmaceutical compan
Press Release: HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, April 25, 2024 TORONTO, April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics Inc Price Target Cut to C$5.00/Share From C$6.50 by Raymond James
HLS Therapeutics Inc Price Target Cut to C$5.00/Share From C$6.50 by Raymond James
Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57
HLS Therapeutics Inc Price Target Cut to C$4.15/Share From C$4.35 by Stifel Nicolaus
HLS Therapeutics Inc Price Target Cut to C$4.15/Share From C$4.35 by Stifel Nicolaus
HLS Therapeutics Inc. (TSE:HLS) Stock Most Popular Amongst Retail Investors Who Own 40%, While Hedge Funds Hold 39%
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
HLS Therapeutics Inc. (HLS.TO), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announced Thursday its Q4 2023 results
HLS Therapeutics Brief: Q4 2023 and Fiscal 2023 Product Sales in Canada Increased 11% and 10%, Respectively, in CAD, Compared to Same Periods in 2022
06:34 AM EDT, 03/14/2024 (MT Newswires) -- HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022
HLS Therapeutics Brief: Q4 2023 Revenue Was US$15.9 Million, Adjusted EBITDA Was $5.3 Million and Cash From Operations Was $3.7 Million
06:34 AM EDT, 03/14/2024 (MT Newswires) -- HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million
HLS Therapeutics Announces Fiscal 2023 Financial Results
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
HLS Therapeutics Inc Price Target Cut to C$4.35/Share From C$5.00 by Stifel Nicolaus
HLS Therapeutics Inc Price Target Cut to C$4.35/Share From C$5.00 by Stifel Nicolaus
HLS Therapeutics Announces CFO Departure
Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated With a 41% Reduction in Total Events Compared With Placebo
05:17 PM EST, 11/14/2023 (MT Newswires) -- HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo